126 related articles for article (PubMed ID: 25832107)
1. Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis.
Ramos JM; Vidal I; Bellot P; Gómez-Hurtado I; Zapater P; Such J
Gut; 2016 Jan; 65(1):182-3. PubMed ID: 25832107
[No Abstract] [Full Text] [Related]
2. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
Husson MO; Izard D; Bryskier A; Leclerc H
Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
[TBL] [Abstract][Full Text] [Related]
3. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153
[TBL] [Abstract][Full Text] [Related]
4. Emergence of resistance to fluoroquinolones among gram positive and gram negative clinical isolates.
Nesar S; Shoaib MH; Rahim N; Rehman R
Pak J Pharm Sci; 2012 Oct; 25(4):877-81. PubMed ID: 23010009
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of norfloxacin against 1700 relatively resistant clinical isolates.
Qadri SM; Lee G; Brodie L
Drugs Exp Clin Res; 1989; 15(8):349-53. PubMed ID: 2598776
[TBL] [Abstract][Full Text] [Related]
6. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activity of norfloxacin against gram-positive and gram-negative organisms from recent clinical isolates].
Mancini C; Brenciaglia MI; Ghezzi MC; Giordano A; Nazzari C; Cipriani P
Boll Ist Sieroter Milan; 1985; 64(4):289-93. PubMed ID: 3935135
[TBL] [Abstract][Full Text] [Related]
8. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
Drugs Exp Clin Res; 1987; 13(9):555-61. PubMed ID: 3480796
[TBL] [Abstract][Full Text] [Related]
9. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.
Brigidi P; Swennen E; Rizzello F; Bozzolasco M; Matteuzzi D
J Chemother; 2002 Jun; 14(3):290-5. PubMed ID: 12120885
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
Moros M; Coll R; Esteve M; Parés J; Xicota MA
Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
[No Abstract] [Full Text] [Related]
11. Fosfomycin.
Falagas ME; Vouloumanou EK; Samonis G; Vardakas KZ
Clin Microbiol Rev; 2016 Apr; 29(2):321-47. PubMed ID: 26960938
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial effect of some essential oils administered alone or in combination with Norfloxacin.
Rosato A; Vitali C; De Laurentis N; Armenise D; Antonietta Milillo M
Phytomedicine; 2007 Nov; 14(11):727-32. PubMed ID: 17303397
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial activity of norfloxacin against bacterial isolates from the urinary tract.
Qadri SM; Johnson S
J Natl Med Assoc; 1989 Apr; 81(4):382-5. PubMed ID: 2738947
[TBL] [Abstract][Full Text] [Related]
14. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis.
Alhanout K; Brunel JM; Raoult D; Rolain JM
J Antimicrob Chemother; 2009 Oct; 64(4):810-4. PubMed ID: 19666647
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin combined with polymyxins: A potential regimen for selective decontamination of multidrug-resistant bacteria in the digestive tract?
Betts JW; Phee LM; Wareham DW
J Glob Antimicrob Resist; 2016 Mar; 4():11-15. PubMed ID: 27436386
[TBL] [Abstract][Full Text] [Related]
16. [Norfloxacin: a broad-spectrum quinolone for superficial eye infections].
Grosset J
Pathol Biol (Paris); 1990 Sep; 38(7):735-41. PubMed ID: 2235090
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro evaluation of activity of tigecycline against susceptible and multidrug resistant organisms.
Gupta V; Bansal N; Chander J
Indian J Med Microbiol; 2012; 30(4):483-5. PubMed ID: 23183481
[No Abstract] [Full Text] [Related]
18. 1-Chloropiperazinic derivative (ER 311) of norfloxacin: antibacterial activity in vitro and pharmacokinetic properties in mice.
Dubini F; Balsari A; Stradi R; Riviera L
Chemioterapia; 1987 Jun; 6(2 Suppl):178-80. PubMed ID: 3509385
[No Abstract] [Full Text] [Related]
19. Susceptibility testing of bacteria and fungi. Report from "the Norwegian Working Group on Antibiotics".
Bergan T; Bruun JN; Digranes A; Lingaas E; Melby KK; Sander J
Scand J Infect Dis Suppl; 1997; 103():1-36. PubMed ID: 9253777
[No Abstract] [Full Text] [Related]
20. Rifaximin--a novel antimicrobial for enteric infections.
Huang DB; DuPont HL
J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
